Biotest AG products

IgG Next Generation is a new development of a polyvalent immungiobulin (NIG) for the treatment of immunedeficiencies and auto immune diseases. IgG Next Generation is manufactured with a new and innovative production process and will be the main product of the new manufacturing site Biotest Next Level.

IgG Next Generation is a new development of a polyvalent immunglobulin (IVIG) for the treatment of immunedeficiencies and auto immune diseases. IgG Next Generation is being manufactured with a new and innovative production process and will be the main product of the new manufacturing site Biotest Next Level.

Trimodulin is an innovative polyvalent antibody composition, purified from human plasma. In comparison to standard IgG preparations (IVIG), trimodulin contains relevant amounts of IgM and IgA in addition to IgG.

Trimodulin (BT588, predecessor BT086) is a human plasma-derived native polyvalent antibody preparation for intravenous administration. Trimodulin contains immunoglobulins IgM (-23%), IgA (~ 21%) and igG (-56%). Trimodulin mediates its mode of action via three potential mechanisms which are; opsonization of causal pathogens, neutralizing of microbial pathogens and their virulence factors (endo- and exotoxins) and targeting the host inflammatory response (anti-inflammatory properties). Currently, trimodulin is under clinical development for severe community-acquired pneumonia (sCAP). These patients suffer from very severe lung infections, and a high number need life saving measures such as mechanical ventilation. The average mortality rate is between 30% and 50%. which makes sCAP one of the main causes of infection-related death in Europe and the USA.

BT-524 is a human fibrinogen concentrate purified from human plasma. Fibrinogen is a plasma protein produced by the liver, which is an important component of blood clotting. A deficiency of autologous fibrinogen means that the blood`s ability to clot is impaired, which leads to a greatly increased risk of bleeding and additionally to a delay in bleeding cessation. In the case of congenital fibrinogen deficiency patients can produce no or only insufficient fibrinogen. In acquired fibrinogen deficiency on the other hand, patients lose fibrinogen because of heavy bleeding, for example due to severe injuries and surgery. In both cases, fibrinogen must be supplied again to stop bleeding.